{"entities": [{"EntityRegistrantName": "HALOZYME THERAPEUTICS, INC.", "TradingSymbol": "HALO", "EntityCentralIndexKey": "1159036", "db": 1, "Industry_SEC": "Biological Products, (No Disgnostic Substances)", "Industry_SEC_db": 2836, "Industry": "Food", "Industry_db": 18, "Region": "California", "Region_db": 5, "SecurityExchangeName": "0", "SECurl": "0", "URL": "", "SEC_Update": "2021-11-11", "SEC_UpdateDateAndTime": null, "SecuritiesUpdate": "2021-06-03T00:00:00Z", "OpinionLastYear": null, "OpinionSecondLastYear": null, "OpinionThirdLastYear": null, "OpinionFourthLastYear": null, "ClockLastYear": 31.0, "ClockSecondLastYear": 16.0, "ClockThirdLastYear": 12.0, "ClockFourthLastYear": 30.0, "BridgeLastYear": "There are still some unexplained differences in the financial statements and it might not be exempt from material misstatements.", "BridgeSecondLastYear": "There are still some unexplained differences in the financial statements and it might not be exempt from material misstatements.", "BridgeThirdLastYear": "There are still some unexplained differences in the financial statements and it might not be exempt from material misstatements.", "BridgeFourthLastYear": "There are still some unexplained differences in the financial statements and it might not be exempt from material misstatements.", "Anomalies": "0", "AnomaliesRatio1": 47.18, "AnomaliesRatio2": 201.16, "AnomaliesRatio3": 58.76, "AnomaliesRatio4": 54.53, "AnomaliesRatio5": 47.11, "AnomaliesRatio6": 39.95, "NumberOfYearsAudited": 0, "CommonSharesIntrinsicValueLastYear": 1651065250, "CommonSharesIntrinsicValueSecondLastYear": 398166750, "CommonSharesIntrinsicValueThirdLastYear": 250815195, "CommonSharesIntrinsicValueFourthLastYear": 857685215, "MarketCapitalizationLastYear": 5302834096, "MarketCapitalizationSecondLastYear": 2450748221, "MarketCapitalizationThirdLastYear": 2121835321, "MarketCapitalizationFourthLastYear": 2898731713, "CommonShareIntrinsicValueLastYear": 12.21, "CommonShareIntrinsicValueSecondLastYear": 2.88, "CommonShareIntrinsicValueThirdLastYear": 1.73, "CommonShareIntrinsicValueFourthLastYear": 5.99, "CommonSharePriceLastYear": 39.2, "CommonSharePriceSecondLastYear": 17.73, "CommonSharePriceThirdLastYear": 14.63, "CommonSharePriceFourthLastYear": 20.26, "CommonSharesOutstandingLastYear": 135276380, "CommonSharesOutstandingSecondLastYear": 138226070, "CommonSharesOutstandingThirdLastYear": 145033173, "CommonSharesOutstandingFourthLastYear": 143076590, "month_end": 12, "lastyear": "2020-12-31", "secondlastyear": "2019-12-31", "thirdlastyear": "2018-12-31", "fourthlastyear": "2017-12-31", "fifthlastyear": "2016-12-31", "sixthlastyear": "2015-12-31", "amendlastyear": "", "amendsecondlastyear": "", "amendthirdlastyear": "", "amendfourthlastyear": "", "amendfifthlastyear": "", "amendsixthlastyear": "", "accessionnumberlastyear": "0001159036-21-000014", "accessionnumbersecondlastyear": "0001159036-20-000013", "accessionnumberthirdlastyear": "0001159036-19-000006", "accessionnumberfourthlastyear": "0001159036-18-000011", "accessionnumberfifthlastyear": "0001159036-17-000014", "accessionnumbersixthlastyear": "0001159036-16-000100", "urlbalancesheetlastyear": "https://www.sec.gov/Archives/edgar/data/1159036/000115903621000014/R3.htm", "urlbalancesheetsecondlastyear": "https://www.sec.gov/Archives/edgar/data/1159036/000115903620000013/R2.htm", "urlbalancesheetthirdlastyear": "https://www.sec.gov/Archives/edgar/data/1159036/000115903619000006/R2.htm", "urlbalancesheetfourthlastyear": "https://www.sec.gov/Archives/edgar/data/1159036/000115903618000011/R2.htm", "urlbalancesheetfifthlastyear": "https://www.sec.gov/Archives/edgar/data/1159036/000115903617000014/R2.htm", "urlbalancesheetsixthlastyear": "https://www.sec.gov/Archives/edgar/data/1159036/000115903616000100/R2.htm", "urlincomestatementlastyear": "https://www.sec.gov/Archives/edgar/data/1159036/000115903621000014/R5.htm", "urlincomestatementsecondlastyear": "https://www.sec.gov/Archives/edgar/data/1159036/000115903620000013/R4.htm", "urlincomestatementthirdlastyear": "https://www.sec.gov/Archives/edgar/data/1159036/000115903619000006/R4.htm", "urlincomestatementfourthlastyear": "https://www.sec.gov/Archives/edgar/data/1159036/000115903618000011/R4.htm", "urlincomestatementfifthlastyear": "https://www.sec.gov/Archives/edgar/data/1159036/000115903617000014/R4.htm", "urlincomestatementsixthlastyear": "https://www.sec.gov/Archives/edgar/data/1159036/000115903616000100/R4.htm", "urlcomprehensiveincomelastyear": "https://www.sec.gov/Archives/edgar/data/1159036/000115903621000014/R6.htm", "urlcomprehensiveincomesecondlastyear": "https://www.sec.gov/Archives/edgar/data/1159036/000115903620000013/R5.htm", "urlcomprehensiveincomethirdlastyear": "https://www.sec.gov/Archives/edgar/data/1159036/000115903619000006/R5.htm", "urlcomprehensiveincomefourthlastyear": "https://www.sec.gov/Archives/edgar/data/1159036/000115903618000011/R5.htm", "urlcomprehensiveincomefifthlastyear": "https://www.sec.gov/Archives/edgar/data/1159036/000115903617000014/R5.htm", "urlcomprehensiveincomesixthlastyear": "https://www.sec.gov/Archives/edgar/data/1159036/000115903616000100/R5.htm", "urlshareholdersequitylastyear": "", "urlshareholdersequitysecondlastyear": "", "urlshareholdersequitythirdlastyear": "", "urlshareholdersequityfourthlastyear": "", "urlshareholdersequityfifthlastyear": "", "urlshareholdersequitysixthlastyear": "", "urlcashflowlastyear": "https://www.sec.gov/Archives/edgar/data/1159036/000115903621000014/R7.htm", "urlcashflowsecondlastyear": "https://www.sec.gov/Archives/edgar/data/1159036/000115903620000013/R6.htm", "urlcashflowthirdlastyear": "https://www.sec.gov/Archives/edgar/data/1159036/000115903619000006/R6.htm", "urlcashflowfourthlastyear": "https://www.sec.gov/Archives/edgar/data/1159036/000115903618000011/R6.htm", "urlcashflowfifthlastyear": "https://www.sec.gov/Archives/edgar/data/1159036/000115903617000014/R6.htm", "urlcashflowsixthlastyear": "https://www.sec.gov/Archives/edgar/data/1159036/000115903616000100/R6.htm", "ad1.db": 0, "ad1.AccessionNumber": "0001159036-21-000014", "ad1.AmendmentFlag": "", "ad1.EntityRegistrantName": "HALOZYME THERAPEUTICS, INC.", "ad1.Period": "lastyear", "ad1.PeriodEndDate": "2020-12-31", "ad1.TradingSymbol": "HALO", "ad1.CurrentAssets": 554764000, "ad1.NonCurrentAssets": 25160000, "ad1.Assets": 0, "ad1.CurrentLiabilities": -421385000, "ad1.NonCurrentLiabilities": -7492000, "ad1.Liabilities": 0, "ad1.ShareholdersEquity": -151047000, "ad1.LiabilitiesAndShareholdersEquity": 0, "ad1.CurrentAssetsGL_i": "", "ad1.CurrentAssetsGL_ii": "", "ad1.CurrentAssetsGL_iii": "", "ad1.AnomalyCurrentAssets": -14207000, "ad1.AnomalyCurrentAssetsSEC": 0, "ad1.NonCurrentAssetsGL_i": "", "ad1.NonCurrentAssetsGL_ii": "", "ad1.NonCurrentAssetsGL_iii": "", "ad1.AnomalyNonCurrentAssets": 0, "ad1.AnomalyNonCurrentAssetsSEC": 0, "ad1.AnomalyAssets": 0, "ad1.CurrentLiabilitiesGL_i": "", "ad1.CurrentLiabilitiesGL_ii": "", "ad1.CurrentLiabilitiesGL_iii": "", "ad1.AnomalyCurrentLiabilities": 0, "ad1.AnomalyCurrentLiabilitiesSEC": 0, "ad1.NonCurrentLiabilitiesGL_i": "", "ad1.NonCurrentLiabilitiesGL_ii": "", "ad1.NonCurrentLiabilitiesGL_iii": "", "ad1.AnomalyNonCurrentLiabilities": 0, "ad1.AnomalyNonCurrentLiabilitiesSEC": 0, "ad1.AnomalyLiabilities": 0, "ad1.AnomalyShareholdersEquity": 625618000, "ad1.ShareholdersEquityBalanceGL_i": "", "ad1.ShareholdersEquityBalanceGL_ii": "", "ad1.ShareholdersEquityBalanceGL_iii": "", "ad1.AnomalyShareholdersEquitySEC": 0, "ad1.AnomalyLiabilitiesAndShareholdersEquity": 0, "ad1.Sales": 0, "ad1.CostOfSales": 0, "ad1.GrossMargin": -224227000, "ad1.OperatingExpenses": 0, "ad1.OperatingIncome": -144255000, "ad1.IncomeBeforeTaxes": -129302000, "ad1.NetIncome": -129085000, "ad1.NetIncomeAttributableToNonControllingInterest": 0, "ad1.GrossMarginGL_i": "", "ad1.GrossMarginGL_ii": "", "ad1.GrossMarginGL_iii": "", "ad1.AnomalyGrossMargin": 0, "ad1.OperatingExpensesGL_i": "", "ad1.OperatingExpensesGL_ii": "", "ad1.OperatingExpensesGL_iii": "", "ad1.AnomalyOperatingExpenses": 0, "ad1.OperatingIncomeGL_i": "", "ad1.OperatingIncomeGL_ii": "", "ad1.OperatingIncomeGL_iii": "", "ad1.AnomalyOperatingIncome": 0, "ad1.IncomeBeforeTaxesGL_i": "", "ad1.IncomeBeforeTaxesGL_ii": "", "ad1.IncomeBeforeTaxesGL_iii": "", "ad1.AnomalyIncomeBeforeTaxes": 0, "ad1.NetIncomeGL_i": "", "ad1.NetIncomeGL_ii": "", "ad1.NetIncomeGL_iii": "", "ad1.AnomalyNetIncome": 0, "ad1.OtherComprehensiveIncome": 218000, "ad1.ComprehensiveIncome": 0, "ad1.OtherComprehensiveIncomeGL_i": "", "ad1.OtherComprehensiveIncomeGL_ii": "", "ad1.OtherComprehensiveIncomeGL_iii": "", "ad1.AnomalyOtherComprehensiveIncome": -22000, "ad1.AnomalyComprehensiveIncome": 0, "ad1.ShareholdersEquityBeginning": 0, "ad1.ConvertibleDebt": 0, "ad1.CommonShares": 0, "ad1.PreferredShares": 0, "ad1.RetainedEarnings": 0, "ad1.AccumulatedOtherComprehensiveIncome": 0, "ad1.TreasuryShares": 0, "ad1.EmployeeBenefitTrust": 0, "ad1.NonControllingInterests": 0, "ad1.AnomalyConvertibleDebt": 0, "ad1.AnomalyCommonShares": -22482000, "ad1.AnomalyPreferredShares": 0, "ad1.AnomalyRetainedEarnings": 157139000, "ad1.AnomalyAccumulatedOtherComprehensiveIncome": 0, "ad1.AnomalyTreasuryShares": 0, "ad1.AnomalyEmployeeBenefitTrust": 0, "ad1.AnomalyNonControllingInterests": 0, "ad1.ShareholdersEquityGL_i": "", "ad1.ShareholdersEquityGL_ii": "", "ad1.ShareholdersEquityGL_iii": "", "ad1.OperatingActivities": 0, "ad1.InvestingActivities": 0, "ad1.FinancingActivities": 0, "ad1.IncreaseDecreaseInCash": 0, "ad1.CashFlowCashExplainedDifference": 500000, "ad1.OperatingActivitiesGL_i": "", "ad1.OperatingActivitiesGL_ii": "", "ad1.OperatingActivitiesGL_iii": "", "ad1.AnomalyOperatingActivities": 0, "ad1.AnomalyOperatingActivitiesSEC": 0, "ad1.InvestingActivitiesGL_i": "", "ad1.InvestingActivitiesGL_ii": "", "ad1.InvestingActivitiesGL_iii": "", "ad1.AnomalyInvestingActivities": 0, "ad1.AnomalyInvestingActivitiesSEC": 0, "ad1.FinancingActivitiesGL_i": "", "ad1.FinancingActivitiesGL_ii": "", "ad1.FinancingActivitiesGL_iii": "", "ad1.AnomalyFinancingActivities": 0, "ad1.AnomalyFinancingActivitiesSEC": 0, "ad1.TargetWorkingCapital": 1.2, "ad1.ReinvestmentOfMaintenance": 2504000, "ad1.NormalizedDividendPaymentToNonControllingInterests": 0, "ad1.NormalizedDividendPaymentToPreferredShareholders": 0, "ad1.TheoricalInterestRate": 0.035, "ad1.TheoricalTaxRate": 0.15, "ad1.CapitalizationRateFloor": 0.021, "ad2.db": 0, "ad2.AccessionNumber": "0001159036-20-000013", "ad2.AmendmentFlag": "", "ad2.EntityRegistrantName": "HALOZYME THERAPEUTICS, INC.", "ad2.Period": "secondlastyear", "ad2.PeriodEndDate": "2019-12-31", "ad2.TradingSymbol": "HALO", "ad2.CurrentAssets": 543436000, "ad2.NonCurrentAssets": 22438000, "ad2.Assets": 0, "ad2.CurrentLiabilities": -89649000, "ad2.NonCurrentLiabilities": -1247000, "ad2.Liabilities": 0, "ad2.ShareholdersEquity": -474978000, "ad2.LiabilitiesAndShareholdersEquity": 0, "ad2.CurrentAssetsGL_i": "", "ad2.CurrentAssetsGL_ii": "", "ad2.CurrentAssetsGL_iii": "", "ad2.AnomalyCurrentAssets": -22290000, "ad2.AnomalyCurrentAssetsSEC": 0, "ad2.NonCurrentAssetsGL_i": "", "ad2.NonCurrentAssetsGL_ii": "", "ad2.NonCurrentAssetsGL_iii": "", "ad2.AnomalyNonCurrentAssets": 0, "ad2.AnomalyNonCurrentAssetsSEC": 0, "ad2.AnomalyAssets": 0, "ad2.CurrentLiabilitiesGL_i": "", "ad2.CurrentLiabilitiesGL_ii": "", "ad2.CurrentLiabilitiesGL_iii": "", "ad2.AnomalyCurrentLiabilities": -8024000, "ad2.AnomalyCurrentLiabilitiesSEC": 0, "ad2.NonCurrentLiabilitiesGL_i": "", "ad2.NonCurrentLiabilitiesGL_ii": "", "ad2.NonCurrentLiabilitiesGL_iii": "", "ad2.AnomalyNonCurrentLiabilities": 387225000, "ad2.AnomalyNonCurrentLiabilitiesSEC": 0, "ad2.AnomalyLiabilities": 0, "ad2.AnomalyShareholdersEquity": 1078416000, "ad2.ShareholdersEquityBalanceGL_i": "", "ad2.ShareholdersEquityBalanceGL_ii": "", "ad2.ShareholdersEquityBalanceGL_iii": "", "ad2.AnomalyShareholdersEquitySEC": 0, "ad2.AnomalyLiabilitiesAndShareholdersEquity": 0, "ad2.Sales": 0, "ad2.CostOfSales": 0, "ad2.GrossMargin": -150446000, "ad2.OperatingExpenses": 0, "ad2.OperatingIncome": 67610000, "ad2.IncomeBeforeTaxes": 72251000, "ad2.NetIncome": 72240000, "ad2.NetIncomeAttributableToNonControllingInterest": 0, "ad2.GrossMarginGL_i": "", "ad2.GrossMarginGL_ii": "", "ad2.GrossMarginGL_iii": "", "ad2.AnomalyGrossMargin": 0, "ad2.OperatingExpensesGL_i": "", "ad2.OperatingExpensesGL_ii": "", "ad2.OperatingExpensesGL_iii": "", "ad2.AnomalyOperatingExpenses": 0, "ad2.OperatingIncomeGL_i": "", "ad2.OperatingIncomeGL_ii": "", "ad2.OperatingIncomeGL_iii": "", "ad2.AnomalyOperatingIncome": 0, "ad2.IncomeBeforeTaxesGL_i": "", "ad2.IncomeBeforeTaxesGL_ii": "", "ad2.IncomeBeforeTaxesGL_iii": "", "ad2.AnomalyIncomeBeforeTaxes": 0, "ad2.NetIncomeGL_i": "", "ad2.NetIncomeGL_ii": "", "ad2.NetIncomeGL_iii": "", "ad2.AnomalyNetIncome": 0, "ad2.OtherComprehensiveIncome": -517000, "ad2.ComprehensiveIncome": 0, "ad2.OtherComprehensiveIncomeGL_i": "", "ad2.OtherComprehensiveIncomeGL_ii": "", "ad2.OtherComprehensiveIncomeGL_iii": "", "ad2.AnomalyOtherComprehensiveIncome": 0, "ad2.AnomalyComprehensiveIncome": 0, "ad2.ShareholdersEquityBeginning": 0, "ad2.ConvertibleDebt": 0, "ad2.CommonShares": 0, "ad2.PreferredShares": 0, "ad2.RetainedEarnings": 0, "ad2.AccumulatedOtherComprehensiveIncome": 0, "ad2.TreasuryShares": 0, "ad2.EmployeeBenefitTrust": 0, "ad2.NonControllingInterests": 0, "ad2.AnomalyConvertibleDebt": 0, "ad2.AnomalyCommonShares": -2527776000, "ad2.AnomalyPreferredShares": 0, "ad2.AnomalyRetainedEarnings": 199998000, "ad2.AnomalyAccumulatedOtherComprehensiveIncome": 0, "ad2.AnomalyTreasuryShares": 0, "ad2.AnomalyEmployeeBenefitTrust": 0, "ad2.AnomalyNonControllingInterests": 0, "ad2.ShareholdersEquityGL_i": "", "ad2.ShareholdersEquityGL_ii": "", "ad2.ShareholdersEquityGL_iii": "", "ad2.OperatingActivities": 0, "ad2.InvestingActivities": 0, "ad2.FinancingActivities": 0, "ad2.IncreaseDecreaseInCash": 0, "ad2.CashFlowCashExplainedDifference": 500000, "ad2.OperatingActivitiesGL_i": "", "ad2.OperatingActivitiesGL_ii": "", "ad2.OperatingActivitiesGL_iii": "", "ad2.AnomalyOperatingActivities": 0, "ad2.AnomalyOperatingActivitiesSEC": 0, "ad2.InvestingActivitiesGL_i": "", "ad2.InvestingActivitiesGL_ii": "", "ad2.InvestingActivitiesGL_iii": "", "ad2.AnomalyInvestingActivities": 0, "ad2.AnomalyInvestingActivitiesSEC": 0, "ad2.FinancingActivitiesGL_i": "", "ad2.FinancingActivitiesGL_ii": "", "ad2.FinancingActivitiesGL_iii": "", "ad2.AnomalyFinancingActivities": 0, "ad2.AnomalyFinancingActivitiesSEC": 0, "ad2.TargetWorkingCapital": 1.2, "ad2.ReinvestmentOfMaintenance": 4040000, "ad2.NormalizedDividendPaymentToNonControllingInterests": 0, "ad2.NormalizedDividendPaymentToPreferredShareholders": 0, "ad2.TheoricalInterestRate": 0.035, "ad2.TheoricalTaxRate": 0.15, "ad2.CapitalizationRateFloor": 0.021, "ad3.db": 0, "ad3.AccessionNumber": "0001159036-19-000006", "ad3.AmendmentFlag": "", "ad3.EntityRegistrantName": "HALOZYME THERAPEUTICS, INC.", "ad3.Period": "thirdlastyear", "ad3.PeriodEndDate": "2018-12-31", "ad3.TradingSymbol": "HALO", "ad3.CurrentAssets": 427849000, "ad3.NonCurrentAssets": 12399000, "ad3.Assets": 0, "ad3.CurrentLiabilities": -149361000, "ad3.NonCurrentLiabilities": -42000000, "ad3.Liabilities": 0, "ad3.ShareholdersEquity": -248887000, "ad3.LiabilitiesAndShareholdersEquity": 0, "ad3.CurrentAssetsGL_i": "", "ad3.CurrentAssetsGL_ii": "", "ad3.CurrentAssetsGL_iii": "", "ad3.AnomalyCurrentAssets": -16259000, "ad3.AnomalyCurrentAssetsSEC": 0, "ad3.NonCurrentAssetsGL_i": "", "ad3.NonCurrentAssetsGL_ii": "", "ad3.NonCurrentAssetsGL_iii": "", "ad3.AnomalyNonCurrentAssets": 0, "ad3.AnomalyNonCurrentAssetsSEC": 0, "ad3.AnomalyAssets": 0, "ad3.CurrentLiabilitiesGL_i": "", "ad3.CurrentLiabilitiesGL_ii": "", "ad3.CurrentLiabilitiesGL_iii": "", "ad3.AnomalyCurrentLiabilities": 0, "ad3.AnomalyCurrentLiabilitiesSEC": 0, "ad3.NonCurrentLiabilitiesGL_i": "", "ad3.NonCurrentLiabilitiesGL_ii": "", "ad3.NonCurrentLiabilitiesGL_iii": "", "ad3.AnomalyNonCurrentLiabilities": 0, "ad3.AnomalyNonCurrentLiabilitiesSEC": 0, "ad3.AnomalyLiabilities": 0, "ad3.AnomalyShareholdersEquity": 780602000, "ad3.ShareholdersEquityBalanceGL_i": "", "ad3.ShareholdersEquityBalanceGL_ii": "", "ad3.ShareholdersEquityBalanceGL_iii": "", "ad3.AnomalyShareholdersEquitySEC": 0, "ad3.AnomalyLiabilitiesAndShareholdersEquity": 0, "ad3.Sales": 0, "ad3.CostOfSales": 0, "ad3.GrossMargin": -141726000, "ad3.OperatingExpenses": 0, "ad3.OperatingIncome": 69330000, "ad3.IncomeBeforeTaxes": 79793000, "ad3.NetIncome": 80330000, "ad3.NetIncomeAttributableToNonControllingInterest": 0, "ad3.GrossMarginGL_i": "", "ad3.GrossMarginGL_ii": "", "ad3.GrossMarginGL_iii": "", "ad3.AnomalyGrossMargin": 0, "ad3.OperatingExpensesGL_i": "", "ad3.OperatingExpensesGL_ii": "", "ad3.OperatingExpensesGL_iii": "", "ad3.AnomalyOperatingExpenses": 0, "ad3.OperatingIncomeGL_i": "", "ad3.OperatingIncomeGL_ii": "", "ad3.OperatingIncomeGL_iii": "", "ad3.AnomalyOperatingIncome": 0, "ad3.IncomeBeforeTaxesGL_i": "", "ad3.IncomeBeforeTaxesGL_ii": "", "ad3.IncomeBeforeTaxesGL_iii": "", "ad3.AnomalyIncomeBeforeTaxes": 0, "ad3.NetIncomeGL_i": "", "ad3.NetIncomeGL_ii": "", "ad3.NetIncomeGL_iii": "", "ad3.AnomalyNetIncome": 0, "ad3.OtherComprehensiveIncome": -173000, "ad3.ComprehensiveIncome": 0, "ad3.OtherComprehensiveIncomeGL_i": "", "ad3.OtherComprehensiveIncomeGL_ii": "", "ad3.OtherComprehensiveIncomeGL_iii": "", "ad3.AnomalyOtherComprehensiveIncome": 0, "ad3.AnomalyComprehensiveIncome": 0, "ad3.ShareholdersEquityBeginning": 0, "ad3.ConvertibleDebt": 0, "ad3.CommonShares": 0, "ad3.PreferredShares": 0, "ad3.RetainedEarnings": 0, "ad3.AccumulatedOtherComprehensiveIncome": 0, "ad3.TreasuryShares": 0, "ad3.EmployeeBenefitTrust": 0, "ad3.NonControllingInterests": 0, "ad3.AnomalyConvertibleDebt": 0, "ad3.AnomalyCommonShares": -37628000, "ad3.AnomalyPreferredShares": 0, "ad3.AnomalyRetainedEarnings": 71263000, "ad3.AnomalyAccumulatedOtherComprehensiveIncome": 0, "ad3.AnomalyTreasuryShares": 0, "ad3.AnomalyEmployeeBenefitTrust": 0, "ad3.AnomalyNonControllingInterests": 0, "ad3.ShareholdersEquityGL_i": "", "ad3.ShareholdersEquityGL_ii": "", "ad3.ShareholdersEquityGL_iii": "", "ad3.OperatingActivities": 0, "ad3.InvestingActivities": 0, "ad3.FinancingActivities": 0, "ad3.IncreaseDecreaseInCash": 0, "ad3.CashFlowCashExplainedDifference": 500000, "ad3.OperatingActivitiesGL_i": "", "ad3.OperatingActivitiesGL_ii": "", "ad3.OperatingActivitiesGL_iii": "", "ad3.AnomalyOperatingActivities": 0, "ad3.AnomalyOperatingActivitiesSEC": 0, "ad3.InvestingActivitiesGL_i": "", "ad3.InvestingActivitiesGL_ii": "", "ad3.InvestingActivitiesGL_iii": "", "ad3.AnomalyInvestingActivities": 0, "ad3.AnomalyInvestingActivitiesSEC": 0, "ad3.FinancingActivitiesGL_i": "", "ad3.FinancingActivitiesGL_ii": "", "ad3.FinancingActivitiesGL_iii": "", "ad3.AnomalyFinancingActivities": 0, "ad3.AnomalyFinancingActivitiesSEC": 0, "ad3.TargetWorkingCapital": 1.2, "ad3.ReinvestmentOfMaintenance": 4663000, "ad3.NormalizedDividendPaymentToNonControllingInterests": 0, "ad3.NormalizedDividendPaymentToPreferredShareholders": 0, "ad3.TheoricalInterestRate": 0.035, "ad3.TheoricalTaxRate": 0.15, "ad3.CapitalizationRateFloor": 0.021, "ad4.db": 0, "ad4.AccessionNumber": "0001159036-18-000011", "ad4.AmendmentFlag": "", "ad4.EntityRegistrantName": "HALOZYME THERAPEUTICS, INC.", "ad4.Period": "fourthlastyear", "ad4.PeriodEndDate": "2017-12-31", "ad4.TradingSymbol": "HALO", "ad4.CurrentAssets": 510372000, "ad4.NonCurrentAssets": 9573000, "ad4.Assets": 0, "ad4.CurrentLiabilities": -131328000, "ad4.NonCurrentLiabilities": -180251000, "ad4.Liabilities": 0, "ad4.ShareholdersEquity": -208366000, "ad4.LiabilitiesAndShareholdersEquity": 0, "ad4.CurrentAssetsGL_i": "", "ad4.CurrentAssetsGL_ii": "", "ad4.CurrentAssetsGL_iii": "", "ad4.AnomalyCurrentAssets": -8326000, "ad4.AnomalyCurrentAssetsSEC": 0, "ad4.NonCurrentAssetsGL_i": "", "ad4.NonCurrentAssetsGL_ii": "", "ad4.NonCurrentAssetsGL_iii": "", "ad4.AnomalyNonCurrentAssets": 0, "ad4.AnomalyNonCurrentAssetsSEC": 0, "ad4.AnomalyAssets": 0, "ad4.CurrentLiabilitiesGL_i": "", "ad4.CurrentLiabilitiesGL_ii": "", "ad4.CurrentLiabilitiesGL_iii": "", "ad4.AnomalyCurrentLiabilities": 0, "ad4.AnomalyCurrentLiabilitiesSEC": 0, "ad4.NonCurrentLiabilitiesGL_i": "", "ad4.NonCurrentLiabilitiesGL_ii": "", "ad4.NonCurrentLiabilitiesGL_iii": "", "ad4.AnomalyNonCurrentLiabilities": 0, "ad4.AnomalyNonCurrentLiabilitiesSEC": 0, "ad4.AnomalyLiabilities": 0, "ad4.AnomalyShareholdersEquity": 731187000, "ad4.ShareholdersEquityBalanceGL_i": "", "ad4.ShareholdersEquityBalanceGL_ii": "", "ad4.ShareholdersEquityBalanceGL_iii": "", "ad4.AnomalyShareholdersEquitySEC": 0, "ad4.AnomalyLiabilitiesAndShareholdersEquity": 0, "ad4.Sales": 0, "ad4.CostOfSales": 0, "ad4.GrossMargin": -285461000, "ad4.OperatingExpenses": 0, "ad4.OperatingIncome": -81002000, "ad4.IncomeBeforeTaxes": -61610000, "ad4.NetIncome": -62971000, "ad4.NetIncomeAttributableToNonControllingInterest": 0, "ad4.GrossMarginGL_i": "", "ad4.GrossMarginGL_ii": "", "ad4.GrossMarginGL_iii": "", "ad4.AnomalyGrossMargin": 63507000, "ad4.OperatingExpensesGL_i": "", "ad4.OperatingExpensesGL_ii": "", "ad4.OperatingExpensesGL_iii": "", "ad4.AnomalyOperatingExpenses": 0, "ad4.OperatingIncomeGL_i": "", "ad4.OperatingIncomeGL_ii": "", "ad4.OperatingIncomeGL_iii": "", "ad4.AnomalyOperatingIncome": 0, "ad4.IncomeBeforeTaxesGL_i": "", "ad4.IncomeBeforeTaxesGL_ii": "", "ad4.IncomeBeforeTaxesGL_iii": "", "ad4.AnomalyIncomeBeforeTaxes": 0, "ad4.NetIncomeGL_i": "", "ad4.NetIncomeGL_ii": "", "ad4.NetIncomeGL_iii": "", "ad4.AnomalyNetIncome": 0, "ad4.OtherComprehensiveIncome": 444000, "ad4.ComprehensiveIncome": 0, "ad4.OtherComprehensiveIncomeGL_i": "", "ad4.OtherComprehensiveIncomeGL_ii": "", "ad4.OtherComprehensiveIncomeGL_iii": "", "ad4.AnomalyOtherComprehensiveIncome": 0, "ad4.AnomalyComprehensiveIncome": 0, "ad4.ShareholdersEquityBeginning": 0, "ad4.ConvertibleDebt": 0, "ad4.CommonShares": 0, "ad4.PreferredShares": 0, "ad4.RetainedEarnings": 0, "ad4.AccumulatedOtherComprehensiveIncome": 0, "ad4.TreasuryShares": 0, "ad4.EmployeeBenefitTrust": 0, "ad4.NonControllingInterests": 0, "ad4.AnomalyConvertibleDebt": 0, "ad4.AnomalyCommonShares": -32466000, "ad4.AnomalyPreferredShares": 0, "ad4.AnomalyRetainedEarnings": 0, "ad4.AnomalyAccumulatedOtherComprehensiveIncome": 0, "ad4.AnomalyTreasuryShares": 0, "ad4.AnomalyEmployeeBenefitTrust": 0, "ad4.AnomalyNonControllingInterests": 0, "ad4.ShareholdersEquityGL_i": "", "ad4.ShareholdersEquityGL_ii": "", "ad4.ShareholdersEquityGL_iii": "", "ad4.OperatingActivities": 0, "ad4.InvestingActivities": 0, "ad4.FinancingActivities": 0, "ad4.IncreaseDecreaseInCash": 0, "ad4.CashFlowCashExplainedDifference": 500000, "ad4.OperatingActivitiesGL_i": "", "ad4.OperatingActivitiesGL_ii": "", "ad4.OperatingActivitiesGL_iii": "", "ad4.AnomalyOperatingActivities": 0, "ad4.AnomalyOperatingActivitiesSEC": 0, "ad4.InvestingActivitiesGL_i": "", "ad4.InvestingActivitiesGL_ii": "", "ad4.InvestingActivitiesGL_iii": "", "ad4.AnomalyInvestingActivities": 0, "ad4.AnomalyInvestingActivitiesSEC": 0, "ad4.FinancingActivitiesGL_i": "", "ad4.FinancingActivitiesGL_ii": "", "ad4.FinancingActivitiesGL_iii": "", "ad4.AnomalyFinancingActivities": 0, "ad4.AnomalyFinancingActivitiesSEC": 0, "ad4.TargetWorkingCapital": 1.2, "ad4.ReinvestmentOfMaintenance": 1350000, "ad4.NormalizedDividendPaymentToNonControllingInterests": 0, "ad4.NormalizedDividendPaymentToPreferredShareholders": 0, "ad4.TheoricalInterestRate": 0.035, "ad4.TheoricalTaxRate": 0.15, "ad4.CapitalizationRateFloor": 0.021, "ad5.db": 0, "ad5.AccessionNumber": "0001159036-17-000014", "ad5.AmendmentFlag": "", "ad5.EntityRegistrantName": "HALOZYME THERAPEUTICS, INC.", "ad5.Period": "fifthlastyear", "ad5.PeriodEndDate": "2016-12-31", "ad5.TradingSymbol": "HALO", "ad5.CurrentAssets": 256532000, "ad5.NonCurrentAssets": 4983000, "ad5.Assets": 0, "ad5.CurrentLiabilities": -54585000, "ad5.NonCurrentLiabilities": -206930000, "ad5.Liabilities": 0, "ad5.ShareholdersEquity": 0, "ad5.LiabilitiesAndShareholdersEquity": 0, "ad5.CurrentAssetsGL_i": "", "ad5.CurrentAssetsGL_ii": "", "ad5.CurrentAssetsGL_iii": "", "ad5.AnomalyCurrentAssets": -21029000, "ad5.AnomalyCurrentAssetsSEC": 0, "ad5.NonCurrentAssetsGL_i": "", "ad5.NonCurrentAssetsGL_ii": "", "ad5.NonCurrentAssetsGL_iii": "", "ad5.AnomalyNonCurrentAssets": 0, "ad5.AnomalyNonCurrentAssetsSEC": 0, "ad5.AnomalyAssets": 0, "ad5.CurrentLiabilitiesGL_i": "", "ad5.CurrentLiabilitiesGL_ii": "", "ad5.CurrentLiabilitiesGL_iii": "", "ad5.AnomalyCurrentLiabilities": 0, "ad5.AnomalyCurrentLiabilitiesSEC": 0, "ad5.NonCurrentLiabilitiesGL_i": "", "ad5.NonCurrentLiabilitiesGL_ii": "", "ad5.NonCurrentLiabilitiesGL_iii": "", "ad5.AnomalyNonCurrentLiabilities": 32481000, "ad5.AnomalyNonCurrentLiabilitiesSEC": 0, "ad5.AnomalyLiabilities": 0, "ad5.AnomalyShareholdersEquity": 585348000, "ad5.ShareholdersEquityBalanceGL_i": "", "ad5.ShareholdersEquityBalanceGL_ii": "", "ad5.ShareholdersEquityBalanceGL_iii": "", "ad5.AnomalyShareholdersEquitySEC": 0, "ad5.AnomalyLiabilitiesAndShareholdersEquity": 0, "ad5.Sales": 0, "ad5.CostOfSales": 0, "ad5.GrossMargin": -113485000, "ad5.OperatingExpenses": 0, "ad5.OperatingIncome": 83210000, "ad5.IncomeBeforeTaxes": 101861000, "ad5.NetIncome": 103023000, "ad5.NetIncomeAttributableToNonControllingInterest": 0, "ad5.GrossMarginGL_i": "", "ad5.GrossMarginGL_ii": "", "ad5.GrossMarginGL_iii": "", "ad5.AnomalyGrossMargin": 50984000, "ad5.OperatingExpensesGL_i": "", "ad5.OperatingExpensesGL_ii": "", "ad5.OperatingExpensesGL_iii": "", "ad5.AnomalyOperatingExpenses": 0, "ad5.OperatingIncomeGL_i": "", "ad5.OperatingIncomeGL_ii": "", "ad5.OperatingIncomeGL_iii": "", "ad5.AnomalyOperatingIncome": 0, "ad5.IncomeBeforeTaxesGL_i": "", "ad5.IncomeBeforeTaxesGL_ii": "", "ad5.IncomeBeforeTaxesGL_iii": "", "ad5.AnomalyIncomeBeforeTaxes": 0, "ad5.NetIncomeGL_i": "", "ad5.NetIncomeGL_ii": "", "ad5.NetIncomeGL_iii": "", "ad5.AnomalyNetIncome": 0, "ad5.OtherComprehensiveIncome": -93000, "ad5.ComprehensiveIncome": 0, "ad5.OtherComprehensiveIncomeGL_i": "", "ad5.OtherComprehensiveIncomeGL_ii": "", "ad5.OtherComprehensiveIncomeGL_iii": "", "ad5.AnomalyOtherComprehensiveIncome": 102930000, "ad5.AnomalyComprehensiveIncome": 0, "ad5.ShareholdersEquityBeginning": 0, "ad5.ConvertibleDebt": 0, "ad5.CommonShares": 0, "ad5.PreferredShares": 0, "ad5.RetainedEarnings": 0, "ad5.AccumulatedOtherComprehensiveIncome": 0, "ad5.TreasuryShares": 0, "ad5.EmployeeBenefitTrust": 0, "ad5.NonControllingInterests": 0, "ad5.AnomalyConvertibleDebt": 0, "ad5.AnomalyCommonShares": -36949000, "ad5.AnomalyPreferredShares": 0, "ad5.AnomalyRetainedEarnings": 339000, "ad5.AnomalyAccumulatedOtherComprehensiveIncome": -102930000, "ad5.AnomalyTreasuryShares": 0, "ad5.AnomalyEmployeeBenefitTrust": 0, "ad5.AnomalyNonControllingInterests": 0, "ad5.ShareholdersEquityGL_i": "", "ad5.ShareholdersEquityGL_ii": "", "ad5.ShareholdersEquityGL_iii": "", "ad5.OperatingActivities": 0, "ad5.InvestingActivities": 0, "ad5.FinancingActivities": 0, "ad5.IncreaseDecreaseInCash": 0, "ad5.CashFlowCashExplainedDifference": 0, "ad5.OperatingActivitiesGL_i": "", "ad5.OperatingActivitiesGL_ii": "", "ad5.OperatingActivitiesGL_iii": "", "ad5.AnomalyOperatingActivities": 0, "ad5.AnomalyOperatingActivitiesSEC": 0, "ad5.InvestingActivitiesGL_i": "", "ad5.InvestingActivitiesGL_ii": "", "ad5.InvestingActivitiesGL_iii": "", "ad5.AnomalyInvestingActivities": 0, "ad5.AnomalyInvestingActivitiesSEC": 0, "ad5.FinancingActivitiesGL_i": "", "ad5.FinancingActivitiesGL_ii": "", "ad5.FinancingActivitiesGL_iii": "", "ad5.AnomalyFinancingActivities": 0, "ad5.AnomalyFinancingActivitiesSEC": 0, "ad5.TargetWorkingCapital": 1.2, "ad5.ReinvestmentOfMaintenance": 3137000, "ad5.NormalizedDividendPaymentToNonControllingInterests": 0, "ad5.NormalizedDividendPaymentToPreferredShareholders": 0, "ad5.TheoricalInterestRate": 0.035, "ad5.TheoricalTaxRate": 0.15, "ad5.CapitalizationRateFloor": 0.021, "ad6.db": 0, "ad6.AccessionNumber": "0001159036-16-000100", "ad6.AmendmentFlag": "", "ad6.EntityRegistrantName": "HALOZYME THERAPEUTICS, INC.", "ad6.Period": "sixthlastyear", "ad6.PeriodEndDate": "2015-12-31", "ad6.TradingSymbol": "HALO", "ad6.CurrentAssets": 171772000, "ad6.NonCurrentAssets": 10017000, "ad6.Assets": 0, "ad6.CurrentLiabilities": -62457000, "ad6.NonCurrentLiabilities": -76333000, "ad6.Liabilities": 0, "ad6.ShareholdersEquity": -42999000, "ad6.LiabilitiesAndShareholdersEquity": 0, "ad6.CurrentAssetsGL_i": "", "ad6.CurrentAssetsGL_ii": "", "ad6.CurrentAssetsGL_iii": "", "ad6.AnomalyCurrentAssets": -15960000, "ad6.AnomalyCurrentAssetsSEC": 0, "ad6.NonCurrentAssetsGL_i": "", "ad6.NonCurrentAssetsGL_ii": "", "ad6.NonCurrentAssetsGL_iii": "", "ad6.AnomalyNonCurrentAssets": 0, "ad6.AnomalyNonCurrentAssetsSEC": 0, "ad6.AnomalyAssets": 0, "ad6.CurrentLiabilitiesGL_i": "", "ad6.CurrentLiabilitiesGL_ii": "", "ad6.CurrentLiabilitiesGL_iii": "", "ad6.AnomalyCurrentLiabilities": 0, "ad6.AnomalyCurrentLiabilitiesSEC": 0, "ad6.NonCurrentLiabilitiesGL_i": "", "ad6.NonCurrentLiabilitiesGL_ii": "", "ad6.NonCurrentLiabilitiesGL_iii": "", "ad6.AnomalyNonCurrentLiabilities": 0, "ad6.AnomalyNonCurrentLiabilitiesSEC": 0, "ad6.AnomalyLiabilities": 0, "ad6.AnomalyShareholdersEquity": 525756000, "ad6.ShareholdersEquityBalanceGL_i": "", "ad6.ShareholdersEquityBalanceGL_ii": "", "ad6.ShareholdersEquityBalanceGL_iii": "", "ad6.AnomalyShareholdersEquitySEC": 0, "ad6.AnomalyLiabilitiesAndShareholdersEquity": 0, "ad6.Sales": 0, "ad6.CostOfSales": 0, "ad6.GrossMargin": -105812000, "ad6.OperatingExpenses": 0, "ad6.OperatingIncome": 27452000, "ad6.IncomeBeforeTaxes": 0, "ad6.NetIncome": 32231000, "ad6.NetIncomeAttributableToNonControllingInterest": 0, "ad6.GrossMarginGL_i": "", "ad6.GrossMarginGL_ii": "", "ad6.GrossMarginGL_iii": "", "ad6.AnomalyGrossMargin": 30975000, "ad6.OperatingExpensesGL_i": "", "ad6.OperatingExpensesGL_ii": "", "ad6.OperatingExpensesGL_iii": "", "ad6.AnomalyOperatingExpenses": 0, "ad6.OperatingIncomeGL_i": "", "ad6.OperatingIncomeGL_ii": "", "ad6.OperatingIncomeGL_iii": "", "ad6.AnomalyOperatingIncome": 0, "ad6.IncomeBeforeTaxesGL_i": "", "ad6.IncomeBeforeTaxesGL_ii": "", "ad6.IncomeBeforeTaxesGL_iii": "", "ad6.AnomalyIncomeBeforeTaxes": 0, "ad6.NetIncomeGL_i": "", "ad6.NetIncomeGL_ii": "", "ad6.NetIncomeGL_iii": "", "ad6.AnomalyNetIncome": -32231000, "ad6.OtherComprehensiveIncome": 0, "ad6.ComprehensiveIncome": 0, "ad6.OtherComprehensiveIncomeGL_i": "", "ad6.OtherComprehensiveIncomeGL_ii": "", "ad6.OtherComprehensiveIncomeGL_iii": "", "ad6.AnomalyOtherComprehensiveIncome": 32231000, "ad6.AnomalyComprehensiveIncome": 0, "ad6.ShareholdersEquityBeginning": 0, "ad6.ConvertibleDebt": 0, "ad6.CommonShares": 0, "ad6.PreferredShares": 0, "ad6.RetainedEarnings": 0, "ad6.AccumulatedOtherComprehensiveIncome": 0, "ad6.TreasuryShares": 0, "ad6.EmployeeBenefitTrust": 0, "ad6.NonControllingInterests": 0, "ad6.AnomalyConvertibleDebt": 0, "ad6.AnomalyCommonShares": 0, "ad6.AnomalyPreferredShares": 0, "ad6.AnomalyRetainedEarnings": 0, "ad6.AnomalyAccumulatedOtherComprehensiveIncome": -32231000, "ad6.AnomalyTreasuryShares": 0, "ad6.AnomalyEmployeeBenefitTrust": 0, "ad6.AnomalyNonControllingInterests": 0, "ad6.ShareholdersEquityGL_i": "", "ad6.ShareholdersEquityGL_ii": "", "ad6.ShareholdersEquityGL_iii": "", "ad6.OperatingActivities": 0, "ad6.InvestingActivities": 0, "ad6.FinancingActivities": 0, "ad6.IncreaseDecreaseInCash": 0, "ad6.CashFlowCashExplainedDifference": 0, "ad6.OperatingActivitiesGL_i": "", "ad6.OperatingActivitiesGL_ii": "", "ad6.OperatingActivitiesGL_iii": "", "ad6.AnomalyOperatingActivities": 0, "ad6.AnomalyOperatingActivitiesSEC": 0, "ad6.InvestingActivitiesGL_i": "", "ad6.InvestingActivitiesGL_ii": "", "ad6.InvestingActivitiesGL_iii": "", "ad6.AnomalyInvestingActivities": 0, "ad6.AnomalyInvestingActivitiesSEC": 0, "ad6.FinancingActivitiesGL_i": "", "ad6.FinancingActivitiesGL_ii": "", "ad6.FinancingActivitiesGL_iii": "", "ad6.AnomalyFinancingActivities": 0, "ad6.AnomalyFinancingActivitiesSEC": 0, "ad6.TargetWorkingCapital": 1.2, "ad6.ReinvestmentOfMaintenance": 2360000, "ad6.NormalizedDividendPaymentToNonControllingInterests": 0, "ad6.NormalizedDividendPaymentToPreferredShareholders": 0, "ad6.TheoricalInterestRate": 0.035, "ad6.TheoricalTaxRate": 0.0, "ad6.CapitalizationRateFloor": 0.021, "cf1.AccessionNumber": "0001159036-21-000014", "cf1.AmendmentFlag": "", "cf1.EntityRegistrantName": "HALOZYME THERAPEUTICS, INC.", "cf1.Period": "lastyear", "cf1.PeriodEndDate": "2020-12-31", "cf1.TradingSymbol": "HALO", "cf1.CashBeginningBalance": 120679000, "cf1.EffectOfExchangeRateOnCash": 0, "cf1.DepreciationDepletionAndAmortization": 3284000, "cf1.GainRelatedToDisposalOrSale": 67000, "cf1.RestructuringAndOtherSpecialCharges": 14713000, "cf1.AccruedEmployeeCompensation": 0, "cf1.ShareBasedCompensation": 17204000, "cf1.IncreaseDecreaseInIncomeTaxExpenseBenefit": 0, "cf1.OtherNonCashIncomeExpense": 0, "cf1.IncreaseDecreaseInAccountsReceivable": -38288000, "cf1.IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": 2518000, "cf1.IncreaseDecreaseInInventories": -31388000, "cf1.IncreaseDecreaseInOtherReceivables": 0, "cf1.IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": -41208000, "cf1.IncreaseDecreaseInContractWithCustomerLiability": -4119000, "cf1.IncreaseDecreaseInRetirementBenefits": 0, "cf1.IncreaseDecreaseFinanceLeaseCurrent": 0, "cf1.IncreaseDecreaseOperatingLeaseCurrent": 0, "cf1.IncreaseDecreaseInFairValueOfDerivativesOperating": 0, "cf1.IncreaseDecreaseInOtherOperatingActivities": 3586000, "cf1.PaymentsToAcquireInvestments": -226185000, "cf1.ProceedsOfInvestments": 305967000, "cf1.PaymentsToAcquirePropertyPlantAndEquipment": -2504000, "cf1.ProceedsFromDisposalsOfPropertyAndEquipment": 1076000, "cf1.PaymentsToAcquireBusinessesAndIntangibles": 0, "cf1.ProceedsFromDisposalsOfBusinessesAndIntangibles": 0, "cf1.ProceedsRelatedToInsuranceSettlement": 0, "cf1.ReveiptOfGovernmentGrants": 0, "cf1.PaymentOfLicenseFee": 0, "cf1.InvestingActivitiesInDiscontinuedOperations": 0, "cf1.OtherInvestingActivities": 0, "cf1.FinanceLeasePrincipalPayments": 0, "cf1.ProceedsFromIssuanceOfCommonShares": 63393000, "cf1.ProceedsFromSharePurchasePlanAndOptionsExercice": 0, "cf1.PaymentsRelatedToTaxWithholdingForShareBasedCompensation": 0, "cf1.PaymentsForRepurchaseOfCommonShares": -150117000, "cf1.PaymentsOfDividends": 0, "cf1.IncreaseDecreaseDeferredContingentConsideration": 0, "cf1.ProceedsFromIssuanceOfLongTermDebt": 0, "cf1.RepaymentsOfLongTermDebt": -19560000, "cf1.FinancingCosts": 0, "cf1.NetChangeInShortTermBorrowings": 0, "cf1.NetChangeInForwardAndHedgesClassifiedAsFinancingActivities": 0, "cf1.NetChangeInNonControllingInterests": 0, "cf1.ProceedsFromRepaymentsOfCommercialPaper": 0, "cf1.RepaymentsOfConvertible": 0, "cf1.IssuanceOfConvertible": 0, "cf1.EquityInvesteeAdvancesRepayments": 0, "cf1.OtherFinancingActivities": 0, "cf1.CashPaidForTaxes": 0, "cf1.CashPaidForInterest": 0, "cf2.AccessionNumber": "0001159036-20-000013", "cf2.AmendmentFlag": "", "cf2.EntityRegistrantName": "HALOZYME THERAPEUTICS, INC.", "cf2.Period": "secondlastyear", "cf2.PeriodEndDate": "2019-12-31", "cf2.TradingSymbol": "HALO", "cf2.CashBeginningBalance": 58436000, "cf2.EffectOfExchangeRateOnCash": 0, "cf2.DepreciationDepletionAndAmortization": 4068000, "cf2.GainRelatedToDisposalOrSale": -1439000, "cf2.RestructuringAndOtherSpecialCharges": 3611000, "cf2.AccruedEmployeeCompensation": 0, "cf2.ShareBasedCompensation": 34776000, "cf2.IncreaseDecreaseInIncomeTaxExpenseBenefit": 0, "cf2.OtherNonCashIncomeExpense": 0, "cf2.IncreaseDecreaseInAccountsReceivable": -29437000, "cf2.IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": -19465000, "cf2.IncreaseDecreaseInInventories": -6734000, "cf2.IncreaseDecreaseInOtherReceivables": 0, "cf2.IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": 4638000, "cf2.IncreaseDecreaseInContractWithCustomerLiability": -3996000, "cf2.IncreaseDecreaseInRetirementBenefits": 0, "cf2.IncreaseDecreaseFinanceLeaseCurrent": 0, "cf2.IncreaseDecreaseOperatingLeaseCurrent": 0, "cf2.IncreaseDecreaseInFairValueOfDerivativesOperating": 0, "cf2.IncreaseDecreaseInOtherOperatingActivities": 795000, "cf2.PaymentsToAcquireInvestments": -389759000, "cf2.ProceedsOfInvestments": 388250000, "cf2.PaymentsToAcquirePropertyPlantAndEquipment": -4040000, "cf2.ProceedsFromDisposalsOfPropertyAndEquipment": 0, "cf2.PaymentsToAcquireBusinessesAndIntangibles": 0, "cf2.ProceedsFromDisposalsOfBusinessesAndIntangibles": 0, "cf2.ProceedsRelatedToInsuranceSettlement": 0, "cf2.ReveiptOfGovernmentGrants": 0, "cf2.PaymentOfLicenseFee": 0, "cf2.InvestingActivitiesInDiscontinuedOperations": 0, "cf2.OtherInvestingActivities": 0, "cf2.FinanceLeasePrincipalPayments": 0, "cf2.ProceedsFromIssuanceOfCommonShares": 14224000, "cf2.ProceedsFromSharePurchasePlanAndOptionsExercice": 0, "cf2.PaymentsRelatedToTaxWithholdingForShareBasedCompensation": 0, "cf2.PaymentsForRepurchaseOfCommonShares": -199998000, "cf2.PaymentsOfDividends": 0, "cf2.IncreaseDecreaseDeferredContingentConsideration": 0, "cf2.ProceedsFromIssuanceOfLongTermDebt": 447350000, "cf2.RepaymentsOfLongTermDebt": -108082000, "cf2.FinancingCosts": -279000, "cf2.NetChangeInShortTermBorrowings": 0, "cf2.NetChangeInForwardAndHedgesClassifiedAsFinancingActivities": 0, "cf2.NetChangeInNonControllingInterests": 0, "cf2.ProceedsFromRepaymentsOfCommercialPaper": 0, "cf2.RepaymentsOfConvertible": 0, "cf2.IssuanceOfConvertible": 0, "cf2.EquityInvesteeAdvancesRepayments": 0, "cf2.OtherFinancingActivities": 0, "cf2.CashPaidForTaxes": 0, "cf2.CashPaidForInterest": 0, "cf3.AccessionNumber": "0001159036-19-000006", "cf3.AmendmentFlag": "", "cf3.EntityRegistrantName": "HALOZYME THERAPEUTICS, INC.", "cf3.Period": "thirdlastyear", "cf3.PeriodEndDate": "2018-12-31", "cf3.TradingSymbol": "HALO", "cf3.CashBeginningBalance": 169240000, "cf3.EffectOfExchangeRateOnCash": 0, "cf3.DepreciationDepletionAndAmortization": 2388000, "cf3.GainRelatedToDisposalOrSale": -3085000, "cf3.RestructuringAndOtherSpecialCharges": 0, "cf3.AccruedEmployeeCompensation": 0, "cf3.ShareBasedCompensation": 35696000, "cf3.IncreaseDecreaseInIncomeTaxExpenseBenefit": 0, "cf3.OtherNonCashIncomeExpense": 1545000, "cf3.IncreaseDecreaseInAccountsReceivable": 11613000, "cf3.IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": -5702000, "cf3.IncreaseDecreaseInInventories": -17480000, "cf3.IncreaseDecreaseInOtherReceivables": 0, "cf3.IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": 5696000, "cf3.IncreaseDecreaseInContractWithCustomerLiability": -2832000, "cf3.IncreaseDecreaseInRetirementBenefits": 0, "cf3.IncreaseDecreaseFinanceLeaseCurrent": 0, "cf3.IncreaseDecreaseOperatingLeaseCurrent": 0, "cf3.IncreaseDecreaseInFairValueOfDerivativesOperating": 0, "cf3.IncreaseDecreaseInOtherOperatingActivities": 2991000, "cf3.PaymentsToAcquireInvestments": -311112000, "cf3.ProceedsOfInvestments": 318268000, "cf3.PaymentsToAcquirePropertyPlantAndEquipment": -4663000, "cf3.ProceedsFromDisposalsOfPropertyAndEquipment": 0, "cf3.PaymentsToAcquireBusinessesAndIntangibles": 0, "cf3.ProceedsFromDisposalsOfBusinessesAndIntangibles": 0, "cf3.ProceedsRelatedToInsuranceSettlement": 0, "cf3.ReveiptOfGovernmentGrants": 0, "cf3.PaymentOfLicenseFee": 0, "cf3.InvestingActivitiesInDiscontinuedOperations": 0, "cf3.OtherInvestingActivities": 0, "cf3.FinanceLeasePrincipalPayments": 0, "cf3.ProceedsFromIssuanceOfCommonShares": 13719000, "cf3.ProceedsFromSharePurchasePlanAndOptionsExercice": 0, "cf3.PaymentsRelatedToTaxWithholdingForShareBasedCompensation": 0, "cf3.PaymentsForRepurchaseOfCommonShares": 0, "cf3.PaymentsOfDividends": 0, "cf3.IncreaseDecreaseDeferredContingentConsideration": 0, "cf3.ProceedsFromIssuanceOfLongTermDebt": 0, "cf3.RepaymentsOfLongTermDebt": -77516000, "cf3.FinancingCosts": 0, "cf3.NetChangeInShortTermBorrowings": 0, "cf3.NetChangeInForwardAndHedgesClassifiedAsFinancingActivities": 0, "cf3.NetChangeInNonControllingInterests": 0, "cf3.ProceedsFromRepaymentsOfCommercialPaper": 0, "cf3.RepaymentsOfConvertible": 0, "cf3.IssuanceOfConvertible": 0, "cf3.EquityInvesteeAdvancesRepayments": 0, "cf3.OtherFinancingActivities": 0, "cf3.CashPaidForTaxes": 0, "cf3.CashPaidForInterest": 0, "cf4.AccessionNumber": "0001159036-18-000011", "cf4.AmendmentFlag": "", "cf4.EntityRegistrantName": "HALOZYME THERAPEUTICS, INC.", "cf4.Period": "fourthlastyear", "cf4.PeriodEndDate": "2017-12-31", "cf4.TradingSymbol": "HALO", "cf4.CashBeginningBalance": 67264000, "cf4.EffectOfExchangeRateOnCash": 0, "cf4.DepreciationDepletionAndAmortization": 2161000, "cf4.GainRelatedToDisposalOrSale": -257000, "cf4.RestructuringAndOtherSpecialCharges": 0, "cf4.AccruedEmployeeCompensation": 0, "cf4.ShareBasedCompensation": 30670000, "cf4.IncreaseDecreaseInIncomeTaxExpenseBenefit": 0, "cf4.OtherNonCashIncomeExpense": 1761000, "cf4.IncreaseDecreaseInAccountsReceivable": -6453000, "cf4.IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": 1850000, "cf4.IncreaseDecreaseInInventories": 9477000, "cf4.IncreaseDecreaseInOtherReceivables": 0, "cf4.IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": 15629000, "cf4.IncreaseDecreaseInContractWithCustomerLiability": -6512000, "cf4.IncreaseDecreaseInRetirementBenefits": 0, "cf4.IncreaseDecreaseFinanceLeaseCurrent": 0, "cf4.IncreaseDecreaseOperatingLeaseCurrent": 0, "cf4.IncreaseDecreaseInFairValueOfDerivativesOperating": 0, "cf4.IncreaseDecreaseInOtherOperatingActivities": 22756000, "cf4.PaymentsToAcquireInvestments": -398187000, "cf4.ProceedsOfInvestments": 235805000, "cf4.PaymentsToAcquirePropertyPlantAndEquipment": -1350000, "cf4.ProceedsFromDisposalsOfPropertyAndEquipment": 0, "cf4.PaymentsToAcquireBusinessesAndIntangibles": 0, "cf4.ProceedsFromDisposalsOfBusinessesAndIntangibles": 0, "cf4.ProceedsRelatedToInsuranceSettlement": 0, "cf4.ReveiptOfGovernmentGrants": 0, "cf4.PaymentOfLicenseFee": 0, "cf4.InvestingActivitiesInDiscontinuedOperations": 0, "cf4.OtherInvestingActivities": 0, "cf4.FinanceLeasePrincipalPayments": 0, "cf4.ProceedsFromIssuanceOfCommonShares": 147650000, "cf4.ProceedsFromSharePurchasePlanAndOptionsExercice": 0, "cf4.PaymentsRelatedToTaxWithholdingForShareBasedCompensation": 0, "cf4.PaymentsForRepurchaseOfCommonShares": 0, "cf4.PaymentsOfDividends": 0, "cf4.IncreaseDecreaseDeferredContingentConsideration": 0, "cf4.ProceedsFromIssuanceOfLongTermDebt": 0, "cf4.RepaymentsOfLongTermDebt": -15995000, "cf4.FinancingCosts": 0, "cf4.NetChangeInShortTermBorrowings": 0, "cf4.NetChangeInForwardAndHedgesClassifiedAsFinancingActivities": 0, "cf4.NetChangeInNonControllingInterests": 0, "cf4.ProceedsFromRepaymentsOfCommercialPaper": 0, "cf4.RepaymentsOfConvertible": 0, "cf4.IssuanceOfConvertible": 0, "cf4.EquityInvesteeAdvancesRepayments": 0, "cf4.OtherFinancingActivities": 0, "cf4.CashPaidForTaxes": 0, "cf4.CashPaidForInterest": 0, "cf5.AccessionNumber": "0001159036-17-000014", "cf5.AmendmentFlag": "", "cf5.EntityRegistrantName": "HALOZYME THERAPEUTICS, INC.", "cf5.Period": "fifthlastyear", "cf5.PeriodEndDate": "2016-12-31", "cf5.TradingSymbol": "HALO", "cf5.CashBeginningBalance": 43292000, "cf5.EffectOfExchangeRateOnCash": 0, "cf5.DepreciationDepletionAndAmortization": 2410000, "cf5.GainRelatedToDisposalOrSale": 560000, "cf5.RestructuringAndOtherSpecialCharges": 0, "cf5.AccruedEmployeeCompensation": 0, "cf5.ShareBasedCompensation": 25585000, "cf5.IncreaseDecreaseInIncomeTaxExpenseBenefit": 0, "cf5.OtherNonCashIncomeExpense": 2896000, "cf5.IncreaseDecreaseInAccountsReceivable": 16730000, "cf5.IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": 5256000, "cf5.IncreaseDecreaseInInventories": -5134000, "cf5.IncreaseDecreaseInOtherReceivables": 0, "cf5.IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": -244000, "cf5.IncreaseDecreaseInContractWithCustomerLiability": -9304000, "cf5.IncreaseDecreaseInRetirementBenefits": 0, "cf5.IncreaseDecreaseFinanceLeaseCurrent": 0, "cf5.IncreaseDecreaseOperatingLeaseCurrent": 0, "cf5.IncreaseDecreaseInFairValueOfDerivativesOperating": 0, "cf5.IncreaseDecreaseInOtherOperatingActivities": 13885000, "cf5.PaymentsToAcquireInvestments": -155412000, "cf5.ProceedsOfInvestments": 81783000, "cf5.PaymentsToAcquirePropertyPlantAndEquipment": -3137000, "cf5.ProceedsFromDisposalsOfPropertyAndEquipment": 0, "cf5.PaymentsToAcquireBusinessesAndIntangibles": 0, "cf5.ProceedsFromDisposalsOfBusinessesAndIntangibles": 0, "cf5.ProceedsRelatedToInsuranceSettlement": 0, "cf5.ReveiptOfGovernmentGrants": 0, "cf5.PaymentOfLicenseFee": 0, "cf5.InvestingActivitiesInDiscontinuedOperations": 0, "cf5.OtherInvestingActivities": 0, "cf5.FinanceLeasePrincipalPayments": 0, "cf5.ProceedsFromIssuanceOfCommonShares": 1865000, "cf5.ProceedsFromSharePurchasePlanAndOptionsExercice": 0, "cf5.PaymentsRelatedToTaxWithholdingForShareBasedCompensation": 0, "cf5.PaymentsForRepurchaseOfCommonShares": 0, "cf5.PaymentsOfDividends": 0, "cf5.IncreaseDecreaseDeferredContingentConsideration": 0, "cf5.ProceedsFromIssuanceOfLongTermDebt": 203006000, "cf5.RepaymentsOfLongTermDebt": -54250000, "cf5.FinancingCosts": 0, "cf5.NetChangeInShortTermBorrowings": 0, "cf5.NetChangeInForwardAndHedgesClassifiedAsFinancingActivities": 0, "cf5.NetChangeInNonControllingInterests": 0, "cf5.ProceedsFromRepaymentsOfCommercialPaper": 0, "cf5.RepaymentsOfConvertible": 0, "cf5.IssuanceOfConvertible": 0, "cf5.EquityInvesteeAdvancesRepayments": 0, "cf5.OtherFinancingActivities": 0, "cf5.CashPaidForTaxes": 0, "cf5.CashPaidForInterest": 0, "cf6.AccessionNumber": "0001159036-16-000100", "cf6.AmendmentFlag": "", "cf6.EntityRegistrantName": "HALOZYME THERAPEUTICS, INC.", "cf6.Period": "sixthlastyear", "cf6.PeriodEndDate": "2015-12-31", "cf6.TradingSymbol": "HALO", "cf6.CashBeginningBalance": 61389000, "cf6.EffectOfExchangeRateOnCash": 0, "cf6.DepreciationDepletionAndAmortization": 1677000, "cf6.GainRelatedToDisposalOrSale": 887000, "cf6.RestructuringAndOtherSpecialCharges": 0, "cf6.AccruedEmployeeCompensation": 0, "cf6.ShareBasedCompensation": 20838000, "cf6.IncreaseDecreaseInIncomeTaxExpenseBenefit": 0, "cf6.OtherNonCashIncomeExpense": 1243000, "cf6.IncreaseDecreaseInAccountsReceivable": -23261000, "cf6.IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": -15774000, "cf6.IncreaseDecreaseInInventories": -3083000, "cf6.IncreaseDecreaseInOtherReceivables": 0, "cf6.IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": 13866000, "cf6.IncreaseDecreaseInContractWithCustomerLiability": -1411000, "cf6.IncreaseDecreaseInRetirementBenefits": 0, "cf6.IncreaseDecreaseFinanceLeaseCurrent": 0, "cf6.IncreaseDecreaseOperatingLeaseCurrent": 0, "cf6.IncreaseDecreaseInFairValueOfDerivativesOperating": 0, "cf6.IncreaseDecreaseInOtherOperatingActivities": 166000, "cf6.PaymentsToAcquireInvestments": -71482000, "cf6.ProceedsOfInvestments": 79730000, "cf6.PaymentsToAcquirePropertyPlantAndEquipment": -2360000, "cf6.ProceedsFromDisposalsOfPropertyAndEquipment": 0, "cf6.PaymentsToAcquireBusinessesAndIntangibles": 0, "cf6.ProceedsFromDisposalsOfBusinessesAndIntangibles": 0, "cf6.ProceedsRelatedToInsuranceSettlement": 0, "cf6.ReveiptOfGovernmentGrants": 0, "cf6.PaymentOfLicenseFee": 0, "cf6.InvestingActivitiesInDiscontinuedOperations": 0, "cf6.OtherInvestingActivities": 0, "cf6.FinanceLeasePrincipalPayments": 0, "cf6.ProceedsFromIssuanceOfCommonShares": 13098000, "cf6.ProceedsFromSharePurchasePlanAndOptionsExercice": 0, "cf6.PaymentsRelatedToTaxWithholdingForShareBasedCompensation": 0, "cf6.PaymentsForRepurchaseOfCommonShares": 0, "cf6.PaymentsOfDividends": 0, "cf6.IncreaseDecreaseDeferredContingentConsideration": 0, "cf6.ProceedsFromIssuanceOfLongTermDebt": 0, "cf6.RepaymentsOfLongTermDebt": 0, "cf6.FinancingCosts": 0, "cf6.NetChangeInShortTermBorrowings": 0, "cf6.NetChangeInForwardAndHedgesClassifiedAsFinancingActivities": 0, "cf6.NetChangeInNonControllingInterests": 0, "cf6.ProceedsFromRepaymentsOfCommercialPaper": 0, "cf6.RepaymentsOfConvertible": 0, "cf6.IssuanceOfConvertible": 0, "cf6.EquityInvesteeAdvancesRepayments": 0, "cf6.OtherFinancingActivities": 0, "cf6.CashPaidForTaxes": 0, "cf6.CashPaidForInterest": 0, "tb1.AccessionNumber": "0001159036-21-000014", "tb1.AmendmentFlag": "", "tb1.EntityRegistrantName": "HALOZYME THERAPEUTICS, INC.", "tb1.Link": "0", "tb1.Period": "lastyear", "tb1.PeriodEndDate": "2020-12-31", "tb1.PeriodOfReport": "0", "tb1.TradingSymbol": "HALO", "tb1.Cash": 147703000, "tb1.ShortTermInvestments": 220310000, "tb1.AccountsReceivable": 97730000, "tb1.WorkInProgress": 0, "tb1.Inventories": 60747000, "tb1.PrepaidExpenses": 14067000, "tb1.NonTradeReceivables": 0, "tb1.PrepaidTaxAssetsCurrent": 0, "tb1.DeferredTaxAssetsCurrent": 0, "tb1.RightOfUseAssetsCurrent": 0, "tb1.OtherCurrentAssets": 14207000, "tb1.DiscontinuedOperationsCurrent": 0, "tb1.LongTermReceivables": 0, "tb1.DeferredCharges": 0, "tb1.Investments": 0, "tb1.PropertyPlantAndEquipment": 10593000, "tb1.OperatingLeaseRightOfUseAssets": 0, "tb1.FinanceLeaseRightOfUseAssets": 0, "tb1.IntangibleAssets": 0, "tb1.Goodwill": 0, "tb1.RefundableTaxAssetsNonCurrent": 0, "tb1.DeferredTaxAssetsNonCurrent": 0, "tb1.DefinedBenefitPensionAndOtherSimilarPlans": 0, "tb1.OtherNonCurrentAssets": 14567000, "tb1.DiscontinuedOperations": 0, "tb1.AccountsPayableAndAccruedLiabilities": -22411000, "tb1.EmployeeCompensationCurrent": 0, "tb1.OperatingLeasesCurrent": 0, "tb1.FinanceLeasesCurrent": 0, "tb1.DeferredRevenueAndDepositsCurrent": -1746000, "tb1.AccruedTaxLiabilities": 0, "tb1.DeferredTaxLiabilitiesCurrent": 0, "tb1.CommercialPapers": 0, "tb1.ShortTermBorrowings": 0, "tb1.OtherCurrentLiabilities": 0, "tb1.DiscontinuedOperationsLiabilitiesCurrent": 0, "tb1.DividendsPayable": 0, "tb1.ShortTermPortionOfLongTermDebt": -397228000, "tb1.LongTermDebt": 0, "tb1.PreferredSharesLiability": 0, "tb1.RetirementBenefits": 0, "tb1.OperatingLeasesNonCurrent": 0, "tb1.FinanceLeasesNonCurrent": 0, "tb1.LeaseIncentiveObligation": 0, "tb1.DeferredRevenueAndDepositsNonCurrent": -4026000, "tb1.ContingentConsideration": 0, "tb1.AccruedTaxLiabilitiesNonCurrent": 0, "tb1.DeferredTaxLiabilitiesNonCurrent": 0, "tb1.OtherNonCurrentLiabilities": -3466000, "tb1.RedeemableNonControllingInterests": 0, "tb1.DiscontinuedOperationsLiabilitiesNonCurrent": 0, "tb1.ConvertibleDebtBeginning": 0, "tb1.CommonSharesBeginning": 0, "tb1.CommonSharesIssued": -5278000, "tb1.ShareBasedCompensation": 5278000, "tb1.PreferredSharesBeginning": 0, "tb1.RetainedEarningsBeginning": 603678000, "tb1.DividendsAndDividendEquivalentsDeclared": 0, "tb1.CommonSharesRepurchasedAndRetired": 157139000, "tb1.ShareBasedCompensationRetainedEarnings": 0, "tb1.EffectOfAdoptionOfNewAccountingPronouncementOrTaxCuts": 0, "tb1.RetainedEarningsOthers": -157139000, "tb1.AccumulatedOtherComprehensiveIncomeBeginning": -240000, "tb1.TreasurySharesBeginning": 0, "tb1.PurchaseAndSellOfTreasuryShares": 0, "tb1.EmployeeBenefitTrustBeginning": 0, "tb1.NonControllingInterestsBeginning": 0, "tb1.DividendsDeclaredToNonControllingInterests": 0, "tb1.AcquisitionOfNonControllingInterests": 0, "tb1.NonControllingInterestsOthers": 0, "tb1.Sales": -123011000, "tb1.CostOfSales": -101216000, "tb1.ResearchAndDevelopment": 34236000, "tb1.SellingGeneralAdministrativeAndMarketing": 45736000, "tb1.ImpairmentRestructuringAndOtherSpecialCharges": 0, "tb1.NonOperatingIncome": 14953000, "tb1.IncomeTaxExpenseBenefit": 217000, "tb1.EquityMethodInvesteesIncome": 0, "tb1.NetIncomeFromDiscontinuedOperations": 0, "tb1.ChangeInForeignCurrencyTranslationAdjustment": 32000, "tb1.ChangeInUnrealizedGainsLossesOnDerivativeInstruments": 0, "tb1.ChangeInUnrealizedGainsLossesOnInvestments": 186000, "tb1.ChangeInDefinedBenefitPensionAndOtherSimilarPlans": 0, "tb1.IncomeTaxOnOtherComprehensiveIncome": 0, "tb2.AccessionNumber": "0001159036-20-000013", "tb2.AmendmentFlag": "", "tb2.EntityRegistrantName": "HALOZYME THERAPEUTICS, INC.", "tb2.Link": "0", "tb2.Period": "secondlastyear", "tb2.PeriodEndDate": "2019-12-31", "tb2.PeriodOfReport": "0", "tb2.TradingSymbol": "HALO", "tb2.Cash": 120179000, "tb2.ShortTermInvestments": 301083000, "tb2.AccountsReceivable": 59442000, "tb2.WorkInProgress": 0, "tb2.Inventories": 29359000, "tb2.PrepaidExpenses": 11083000, "tb2.NonTradeReceivables": 0, "tb2.PrepaidTaxAssetsCurrent": 0, "tb2.DeferredTaxAssetsCurrent": 0, "tb2.RightOfUseAssetsCurrent": 0, "tb2.OtherCurrentAssets": 22290000, "tb2.DiscontinuedOperationsCurrent": 0, "tb2.LongTermReceivables": 0, "tb2.DeferredCharges": 0, "tb2.Investments": 0, "tb2.PropertyPlantAndEquipment": 10855000, "tb2.OperatingLeaseRightOfUseAssets": 0, "tb2.FinanceLeaseRightOfUseAssets": 0, "tb2.IntangibleAssets": 0, "tb2.Goodwill": 0, "tb2.RefundableTaxAssetsNonCurrent": 0, "tb2.DeferredTaxAssetsNonCurrent": 0, "tb2.DefinedBenefitPensionAndOtherSimilarPlans": 0, "tb2.OtherNonCurrentAssets": 11583000, "tb2.DiscontinuedOperations": 0, "tb2.AccountsPayableAndAccruedLiabilities": -62083000, "tb2.EmployeeCompensationCurrent": 0, "tb2.OperatingLeasesCurrent": 0, "tb2.FinanceLeasesCurrent": 0, "tb2.DeferredRevenueAndDepositsCurrent": 0, "tb2.AccruedTaxLiabilities": 0, "tb2.DeferredTaxLiabilitiesCurrent": 0, "tb2.CommercialPapers": 0, "tb2.ShortTermBorrowings": 0, "tb2.OtherCurrentLiabilities": -8024000, "tb2.DiscontinuedOperationsLiabilitiesCurrent": 0, "tb2.DividendsPayable": 0, "tb2.ShortTermPortionOfLongTermDebt": -19542000, "tb2.LongTermDebt": -383045000, "tb2.PreferredSharesLiability": 0, "tb2.RetirementBenefits": 0, "tb2.OperatingLeasesNonCurrent": 0, "tb2.FinanceLeasesNonCurrent": 0, "tb2.LeaseIncentiveObligation": 0, "tb2.DeferredRevenueAndDepositsNonCurrent": -1247000, "tb2.ContingentConsideration": 0, "tb2.AccruedTaxLiabilitiesNonCurrent": 0, "tb2.DeferredTaxLiabilitiesNonCurrent": 0, "tb2.OtherNonCurrentLiabilities": 383045000, "tb2.RedeemableNonControllingInterests": 0, "tb2.DiscontinuedOperationsLiabilitiesNonCurrent": 0, "tb2.ConvertibleDebtBeginning": 0, "tb2.CommonSharesBeginning": 0, "tb2.CommonSharesIssued": -2493000000, "tb2.ShareBasedCompensation": 2493000000, "tb2.PreferredSharesBeginning": 0, "tb2.RetainedEarningsBeginning": 531438000, "tb2.DividendsAndDividendEquivalentsDeclared": 0, "tb2.CommonSharesRepurchasedAndRetired": 199998000, "tb2.ShareBasedCompensationRetainedEarnings": 0, "tb2.EffectOfAdoptionOfNewAccountingPronouncementOrTaxCuts": 0, "tb2.RetainedEarningsOthers": -199998000, "tb2.AccumulatedOtherComprehensiveIncomeBeginning": 277000, "tb2.TreasurySharesBeginning": 0, "tb2.PurchaseAndSellOfTreasuryShares": 0, "tb2.EmployeeBenefitTrustBeginning": 0, "tb2.NonControllingInterestsBeginning": 0, "tb2.DividendsDeclaredToNonControllingInterests": 0, "tb2.AcquisitionOfNonControllingInterests": 0, "tb2.NonControllingInterestsOthers": 0, "tb2.Sales": -60045000, "tb2.CostOfSales": -90401000, "tb2.ResearchAndDevelopment": 140804000, "tb2.SellingGeneralAdministrativeAndMarketing": 77252000, "tb2.ImpairmentRestructuringAndOtherSpecialCharges": 0, "tb2.NonOperatingIncome": 4641000, "tb2.IncomeTaxExpenseBenefit": -11000, "tb2.EquityMethodInvesteesIncome": 0, "tb2.NetIncomeFromDiscontinuedOperations": 0, "tb2.ChangeInForeignCurrencyTranslationAdjustment": -9000, "tb2.ChangeInUnrealizedGainsLossesOnDerivativeInstruments": 0, "tb2.ChangeInUnrealizedGainsLossesOnInvestments": -508000, "tb2.ChangeInDefinedBenefitPensionAndOtherSimilarPlans": 0, "tb2.IncomeTaxOnOtherComprehensiveIncome": 0, "tb3.AccessionNumber": "0001159036-19-000006", "tb3.AmendmentFlag": "", "tb3.EntityRegistrantName": "HALOZYME THERAPEUTICS, INC.", "tb3.Link": "0", "tb3.Period": "thirdlastyear", "tb3.PeriodEndDate": "2018-12-31", "tb3.PeriodOfReport": "0", "tb3.TradingSymbol": "HALO", "tb3.Cash": 57936000, "tb3.ShortTermInvestments": 296590000, "tb3.AccountsReceivable": 30005000, "tb3.WorkInProgress": 0, "tb3.Inventories": 22625000, "tb3.PrepaidExpenses": 4434000, "tb3.NonTradeReceivables": 0, "tb3.PrepaidTaxAssetsCurrent": 0, "tb3.DeferredTaxAssetsCurrent": 0, "tb3.RightOfUseAssetsCurrent": 0, "tb3.OtherCurrentAssets": 16259000, "tb3.DiscontinuedOperationsCurrent": 0, "tb3.LongTermReceivables": 0, "tb3.DeferredCharges": 0, "tb3.Investments": 0, "tb3.PropertyPlantAndEquipment": 7465000, "tb3.OperatingLeaseRightOfUseAssets": 0, "tb3.FinanceLeaseRightOfUseAssets": 0, "tb3.IntangibleAssets": 0, "tb3.Goodwill": 0, "tb3.RefundableTaxAssetsNonCurrent": 0, "tb3.DeferredTaxAssetsNonCurrent": 0, "tb3.DefinedBenefitPensionAndOtherSimilarPlans": 0, "tb3.OtherNonCurrentAssets": 4934000, "tb3.DiscontinuedOperations": 0, "tb3.AccountsPayableAndAccruedLiabilities": -53608000, "tb3.EmployeeCompensationCurrent": 0, "tb3.OperatingLeasesCurrent": 0, "tb3.FinanceLeasesCurrent": 0, "tb3.DeferredRevenueAndDepositsCurrent": -4247000, "tb3.AccruedTaxLiabilities": 0, "tb3.DeferredTaxLiabilitiesCurrent": 0, "tb3.CommercialPapers": 0, "tb3.ShortTermBorrowings": 0, "tb3.OtherCurrentLiabilities": 0, "tb3.DiscontinuedOperationsLiabilitiesCurrent": 0, "tb3.DividendsPayable": 0, "tb3.ShortTermPortionOfLongTermDebt": -91506000, "tb3.LongTermDebt": -34874000, "tb3.PreferredSharesLiability": 0, "tb3.RetirementBenefits": 0, "tb3.OperatingLeasesNonCurrent": 0, "tb3.FinanceLeasesNonCurrent": 0, "tb3.LeaseIncentiveObligation": 0, "tb3.DeferredRevenueAndDepositsNonCurrent": -5008000, "tb3.ContingentConsideration": 0, "tb3.AccruedTaxLiabilitiesNonCurrent": 0, "tb3.DeferredTaxLiabilitiesNonCurrent": 0, "tb3.OtherNonCurrentLiabilities": -2118000, "tb3.RedeemableNonControllingInterests": 0, "tb3.DiscontinuedOperationsLiabilitiesNonCurrent": 0, "tb3.ConvertibleDebtBeginning": 0, "tb3.CommonSharesBeginning": 0, "tb3.CommonSharesIssued": -1932000, "tb3.ShareBasedCompensation": 1932000, "tb3.PreferredSharesBeginning": 0, "tb3.RetainedEarningsBeginning": 522371000, "tb3.DividendsAndDividendEquivalentsDeclared": 0, "tb3.CommonSharesRepurchasedAndRetired": 0, "tb3.ShareBasedCompensationRetainedEarnings": 0, "tb3.EffectOfAdoptionOfNewAccountingPronouncementOrTaxCuts": 0, "tb3.RetainedEarningsOthers": -71263000, "tb3.AccumulatedOtherComprehensiveIncomeBeginning": 450000, "tb3.TreasurySharesBeginning": 0, "tb3.PurchaseAndSellOfTreasuryShares": 0, "tb3.EmployeeBenefitTrustBeginning": 0, "tb3.NonControllingInterestsBeginning": 0, "tb3.DividendsDeclaredToNonControllingInterests": 0, "tb3.AcquisitionOfNonControllingInterests": 0, "tb3.NonControllingInterestsOthers": 0, "tb3.Sales": -151862000, "tb3.CostOfSales": 10136000, "tb3.ResearchAndDevelopment": 150252000, "tb3.SellingGeneralAdministrativeAndMarketing": 60804000, "tb3.ImpairmentRestructuringAndOtherSpecialCharges": 0, "tb3.NonOperatingIncome": 10463000, "tb3.IncomeTaxExpenseBenefit": 537000, "tb3.EquityMethodInvesteesIncome": 0, "tb3.NetIncomeFromDiscontinuedOperations": 0, "tb3.ChangeInForeignCurrencyTranslationAdjustment": 9000, "tb3.ChangeInUnrealizedGainsLossesOnDerivativeInstruments": 0, "tb3.ChangeInUnrealizedGainsLossesOnInvestments": -182000, "tb3.ChangeInDefinedBenefitPensionAndOtherSimilarPlans": 0, "tb3.IncomeTaxOnOtherComprehensiveIncome": 0, "tb4.AccessionNumber": "0001159036-18-000011", "tb4.AmendmentFlag": "", "tb4.EntityRegistrantName": "HALOZYME THERAPEUTICS, INC.", "tb4.Link": "0", "tb4.Period": "fourthlastyear", "tb4.PeriodEndDate": "2017-12-31", "tb4.PeriodOfReport": "0", "tb4.TradingSymbol": "HALO", "tb4.Cash": 168740000, "tb4.ShortTermInvestments": 300474000, "tb4.AccountsReceivable": 22133000, "tb4.WorkInProgress": 0, "tb4.Inventories": 5146000, "tb4.PrepaidExpenses": 5553000, "tb4.NonTradeReceivables": 0, "tb4.PrepaidTaxAssetsCurrent": 0, "tb4.DeferredTaxAssetsCurrent": 0, "tb4.RightOfUseAssetsCurrent": 0, "tb4.OtherCurrentAssets": 8326000, "tb4.DiscontinuedOperationsCurrent": 0, "tb4.LongTermReceivables": 0, "tb4.DeferredCharges": 0, "tb4.Investments": 0, "tb4.PropertyPlantAndEquipment": 3520000, "tb4.OperatingLeaseRightOfUseAssets": 0, "tb4.FinanceLeaseRightOfUseAssets": 0, "tb4.IntangibleAssets": 0, "tb4.Goodwill": 0, "tb4.RefundableTaxAssetsNonCurrent": 0, "tb4.DeferredTaxAssetsNonCurrent": 0, "tb4.DefinedBenefitPensionAndOtherSimilarPlans": 0, "tb4.OtherNonCurrentAssets": 6053000, "tb4.DiscontinuedOperations": 0, "tb4.AccountsPayableAndAccruedLiabilities": -47549000, "tb4.EmployeeCompensationCurrent": 0, "tb4.OperatingLeasesCurrent": 0, "tb4.FinanceLeasesCurrent": 0, "tb4.DeferredRevenueAndDepositsCurrent": -6568000, "tb4.AccruedTaxLiabilities": 0, "tb4.DeferredTaxLiabilitiesCurrent": 0, "tb4.CommercialPapers": 0, "tb4.ShortTermBorrowings": 0, "tb4.OtherCurrentLiabilities": 0, "tb4.DiscontinuedOperationsLiabilitiesCurrent": 0, "tb4.DividendsPayable": 0, "tb4.ShortTermPortionOfLongTermDebt": -77211000, "tb4.LongTermDebt": -125140000, "tb4.PreferredSharesLiability": 0, "tb4.RetirementBenefits": 0, "tb4.OperatingLeasesNonCurrent": 0, "tb4.FinanceLeasesNonCurrent": 0, "tb4.LeaseIncentiveObligation": 0, "tb4.DeferredRevenueAndDepositsNonCurrent": -54297000, "tb4.ContingentConsideration": 0, "tb4.AccruedTaxLiabilitiesNonCurrent": 0, "tb4.DeferredTaxLiabilitiesNonCurrent": 0, "tb4.OtherNonCurrentLiabilities": -814000, "tb4.RedeemableNonControllingInterests": 0, "tb4.DiscontinuedOperationsLiabilitiesNonCurrent": 0, "tb4.ConvertibleDebtBeginning": 0, "tb4.CommonSharesBeginning": 0, "tb4.CommonSharesIssued": -1796000, "tb4.ShareBasedCompensation": 1796000, "tb4.PreferredSharesBeginning": 0, "tb4.RetainedEarningsBeginning": 585342000, "tb4.DividendsAndDividendEquivalentsDeclared": 0, "tb4.CommonSharesRepurchasedAndRetired": 0, "tb4.ShareBasedCompensationRetainedEarnings": 0, "tb4.EffectOfAdoptionOfNewAccountingPronouncementOrTaxCuts": 0, "tb4.RetainedEarningsOthers": 0, "tb4.AccumulatedOtherComprehensiveIncomeBeginning": 6000, "tb4.TreasurySharesBeginning": 0, "tb4.PurchaseAndSellOfTreasuryShares": 0, "tb4.EmployeeBenefitTrustBeginning": 0, "tb4.NonControllingInterestsBeginning": 0, "tb4.DividendsDeclaredToNonControllingInterests": 0, "tb4.AcquisitionOfNonControllingInterests": 0, "tb4.NonControllingInterestsOthers": 0, "tb4.Sales": -316613000, "tb4.CostOfSales": 31152000, "tb4.ResearchAndDevelopment": 150643000, "tb4.SellingGeneralAdministrativeAndMarketing": 53816000, "tb4.ImpairmentRestructuringAndOtherSpecialCharges": 0, "tb4.NonOperatingIncome": 19392000, "tb4.IncomeTaxExpenseBenefit": -1361000, "tb4.EquityMethodInvesteesIncome": 0, "tb4.NetIncomeFromDiscontinuedOperations": 0, "tb4.ChangeInForeignCurrencyTranslationAdjustment": 14000, "tb4.ChangeInUnrealizedGainsLossesOnDerivativeInstruments": 0, "tb4.ChangeInUnrealizedGainsLossesOnInvestments": 430000, "tb4.ChangeInDefinedBenefitPensionAndOtherSimilarPlans": 0, "tb4.IncomeTaxOnOtherComprehensiveIncome": 0, "tb5.AccessionNumber": "0001159036-17-000014", "tb5.AmendmentFlag": "", "tb5.EntityRegistrantName": "HALOZYME THERAPEUTICS, INC.", "tb5.Link": "0", "tb5.Period": "fifthlastyear", "tb5.PeriodEndDate": "2016-12-31", "tb5.PeriodOfReport": "0", "tb5.TradingSymbol": "HALO", "tb5.Cash": 66764000, "tb5.ShortTermInvestments": 138217000, "tb5.AccountsReceivable": 15680000, "tb5.WorkInProgress": 0, "tb5.Inventories": 14623000, "tb5.PrepaidExpenses": 219000, "tb5.NonTradeReceivables": 0, "tb5.PrepaidTaxAssetsCurrent": 0, "tb5.DeferredTaxAssetsCurrent": 0, "tb5.RightOfUseAssetsCurrent": 0, "tb5.OtherCurrentAssets": 21029000, "tb5.DiscontinuedOperationsCurrent": 0, "tb5.LongTermReceivables": 0, "tb5.DeferredCharges": 0, "tb5.Investments": 0, "tb5.PropertyPlantAndEquipment": 4264000, "tb5.OperatingLeaseRightOfUseAssets": 0, "tb5.FinanceLeaseRightOfUseAssets": 0, "tb5.IntangibleAssets": 0, "tb5.Goodwill": 0, "tb5.RefundableTaxAssetsNonCurrent": 0, "tb5.DeferredTaxAssetsNonCurrent": 0, "tb5.DefinedBenefitPensionAndOtherSimilarPlans": 0, "tb5.OtherNonCurrentAssets": 719000, "tb5.DiscontinuedOperations": 0, "tb5.AccountsPayableAndAccruedLiabilities": -32399000, "tb5.EmployeeCompensationCurrent": 0, "tb5.OperatingLeasesCurrent": 0, "tb5.FinanceLeasesCurrent": 0, "tb5.DeferredRevenueAndDepositsCurrent": -4793000, "tb5.AccruedTaxLiabilities": 0, "tb5.DeferredTaxLiabilitiesCurrent": 0, "tb5.CommercialPapers": 0, "tb5.ShortTermBorrowings": 0, "tb5.OtherCurrentLiabilities": 0, "tb5.DiscontinuedOperationsLiabilitiesCurrent": 0, "tb5.DividendsPayable": 0, "tb5.ShortTermPortionOfLongTermDebt": -17393000, "tb5.LongTermDebt": -199228000, "tb5.PreferredSharesLiability": 0, "tb5.RetirementBenefits": 0, "tb5.OperatingLeasesNonCurrent": 0, "tb5.FinanceLeasesNonCurrent": 0, "tb5.LeaseIncentiveObligation": 0, "tb5.DeferredRevenueAndDepositsNonCurrent": -39825000, "tb5.ContingentConsideration": 0, "tb5.AccruedTaxLiabilitiesNonCurrent": 0, "tb5.DeferredTaxLiabilitiesNonCurrent": 0, "tb5.OtherNonCurrentLiabilities": 32123000, "tb5.RedeemableNonControllingInterests": 0, "tb5.DiscontinuedOperationsLiabilitiesNonCurrent": 0, "tb5.ConvertibleDebtBeginning": 0, "tb5.CommonSharesBeginning": 0, "tb5.CommonSharesIssued": -11364000, "tb5.ShareBasedCompensation": 11364000, "tb5.PreferredSharesBeginning": 0, "tb5.RetainedEarningsBeginning": 482658000, "tb5.DividendsAndDividendEquivalentsDeclared": 0, "tb5.CommonSharesRepurchasedAndRetired": 0, "tb5.ShareBasedCompensationRetainedEarnings": 0, "tb5.EffectOfAdoptionOfNewAccountingPronouncementOrTaxCuts": 0, "tb5.RetainedEarningsOthers": -339000, "tb5.AccumulatedOtherComprehensiveIncomeBeginning": 99000, "tb5.TreasurySharesBeginning": 0, "tb5.PurchaseAndSellOfTreasuryShares": 0, "tb5.EmployeeBenefitTrustBeginning": 0, "tb5.NonControllingInterestsBeginning": 0, "tb5.DividendsDeclaredToNonControllingInterests": 0, "tb5.AcquisitionOfNonControllingInterests": 0, "tb5.NonControllingInterestsOthers": 0, "tb5.Sales": -146691000, "tb5.CostOfSales": 33206000, "tb5.ResearchAndDevelopment": 150842000, "tb5.SellingGeneralAdministrativeAndMarketing": 45853000, "tb5.ImpairmentRestructuringAndOtherSpecialCharges": 0, "tb5.NonOperatingIncome": 18651000, "tb5.IncomeTaxExpenseBenefit": 1162000, "tb5.EquityMethodInvesteesIncome": 0, "tb5.NetIncomeFromDiscontinuedOperations": 0, "tb5.ChangeInForeignCurrencyTranslationAdjustment": 0, "tb5.ChangeInUnrealizedGainsLossesOnDerivativeInstruments": 0, "tb5.ChangeInUnrealizedGainsLossesOnInvestments": -93000, "tb5.ChangeInDefinedBenefitPensionAndOtherSimilarPlans": 0, "tb5.IncomeTaxOnOtherComprehensiveIncome": 0, "tb6.AccessionNumber": "0001159036-16-000100", "tb6.AmendmentFlag": "", "tb6.EntityRegistrantName": "HALOZYME THERAPEUTICS, INC.", "tb6.Link": "0", "tb6.Period": "sixthlastyear", "tb6.PeriodEndDate": "2015-12-31", "tb6.PeriodOfReport": "0", "tb6.TradingSymbol": "HALO", "tb6.Cash": 43292000, "tb6.ShortTermInvestments": 65047000, "tb6.AccountsReceivable": 32410000, "tb6.WorkInProgress": 0, "tb6.Inventories": 9489000, "tb6.PrepaidExpenses": 5574000, "tb6.NonTradeReceivables": 0, "tb6.PrepaidTaxAssetsCurrent": 0, "tb6.DeferredTaxAssetsCurrent": 0, "tb6.RightOfUseAssetsCurrent": 0, "tb6.OtherCurrentAssets": 15960000, "tb6.DiscontinuedOperationsCurrent": 0, "tb6.LongTermReceivables": 0, "tb6.DeferredCharges": 0, "tb6.Investments": 0, "tb6.PropertyPlantAndEquipment": 3943000, "tb6.OperatingLeaseRightOfUseAssets": 0, "tb6.FinanceLeaseRightOfUseAssets": 0, "tb6.IntangibleAssets": 0, "tb6.Goodwill": 0, "tb6.RefundableTaxAssetsNonCurrent": 0, "tb6.DeferredTaxAssetsNonCurrent": 0, "tb6.DefinedBenefitPensionAndOtherSimilarPlans": 0, "tb6.OtherNonCurrentAssets": 6074000, "tb6.DiscontinuedOperations": 0, "tb6.AccountsPayableAndAccruedLiabilities": -31291000, "tb6.EmployeeCompensationCurrent": 0, "tb6.OperatingLeasesCurrent": 0, "tb6.FinanceLeasesCurrent": 0, "tb6.DeferredRevenueAndDepositsCurrent": -9304000, "tb6.AccruedTaxLiabilities": 0, "tb6.DeferredTaxLiabilitiesCurrent": 0, "tb6.CommercialPapers": 0, "tb6.ShortTermBorrowings": 0, "tb6.OtherCurrentLiabilities": 0, "tb6.DiscontinuedOperationsLiabilitiesCurrent": 0, "tb6.DividendsPayable": 0, "tb6.ShortTermPortionOfLongTermDebt": -21862000, "tb6.LongTermDebt": -27971000, "tb6.PreferredSharesLiability": 0, "tb6.RetirementBenefits": 0, "tb6.OperatingLeasesNonCurrent": 0, "tb6.FinanceLeasesNonCurrent": 0, "tb6.LeaseIncentiveObligation": 0, "tb6.DeferredRevenueAndDepositsNonCurrent": -43919000, "tb6.ContingentConsideration": 0, "tb6.AccruedTaxLiabilitiesNonCurrent": 0, "tb6.DeferredTaxLiabilitiesNonCurrent": 0, "tb6.OtherNonCurrentLiabilities": -4443000, "tb6.RedeemableNonControllingInterests": 0, "tb6.DiscontinuedOperationsLiabilitiesNonCurrent": 0, "tb6.ConvertibleDebtBeginning": 0, "tb6.CommonSharesBeginning": 152551000, "tb6.CommonSharesIssued": -131713000, "tb6.ShareBasedCompensation": -20838000, "tb6.PreferredSharesBeginning": 0, "tb6.RetainedEarningsBeginning": 450427000, "tb6.DividendsAndDividendEquivalentsDeclared": 0, "tb6.CommonSharesRepurchasedAndRetired": 0, "tb6.ShareBasedCompensationRetainedEarnings": 0, "tb6.EffectOfAdoptionOfNewAccountingPronouncementOrTaxCuts": 0, "tb6.RetainedEarningsOthers": 0, "tb6.AccumulatedOtherComprehensiveIncomeBeginning": 99000, "tb6.TreasurySharesBeginning": 0, "tb6.PurchaseAndSellOfTreasuryShares": 0, "tb6.EmployeeBenefitTrustBeginning": 0, "tb6.NonControllingInterestsBeginning": 0, "tb6.DividendsDeclaredToNonControllingInterests": 0, "tb6.AcquisitionOfNonControllingInterests": 0, "tb6.NonControllingInterestsOthers": 0, "tb6.Sales": -135057000, "tb6.CostOfSales": 29245000, "tb6.ResearchAndDevelopment": 93236000, "tb6.SellingGeneralAdministrativeAndMarketing": 40028000, "tb6.ImpairmentRestructuringAndOtherSpecialCharges": 0, "tb6.NonOperatingIncome": -27452000, "tb6.IncomeTaxExpenseBenefit": 0, "tb6.EquityMethodInvesteesIncome": 0, "tb6.NetIncomeFromDiscontinuedOperations": 0, "tb6.ChangeInForeignCurrencyTranslationAdjustment": 0, "tb6.ChangeInUnrealizedGainsLossesOnDerivativeInstruments": 0, "tb6.ChangeInUnrealizedGainsLossesOnInvestments": 0, "tb6.ChangeInDefinedBenefitPensionAndOtherSimilarPlans": 0, "tb6.IncomeTaxOnOtherComprehensiveIncome": 0}]}